Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Procter & Gamble Health's PEG Ratio or its related term are showing as below:
BOM:500126'
s PEG Ratio Range Over the Past 10 Years
Min: 1.19 Med: 2.59 Max: 8.11
Current: 2.22
During the past 13 years, Procter & Gamble Health's highest PEG Ratio was 8.11. The lowest was 1.19. And the median was 2.59.
BOM:500126's PEG Ratio is ranked worse than 57.55% of 351
companies
in the Drug Manufacturers industry
Industry Median: 1.72
vs BOM:500126: 2.22
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Procter & Gamble Health (BOM:500126) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Procter & Gamble Health (BOM:500126) has a PEG Ratio of 2.14 as of Aug. 04, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Procter & Gamble Health and its competitors. This is 17% below median its historical median of 2.59. Over the past decade, Procter & Gamble Health's PEG Ratio has ranged from 1.19 to 8.11. According to the industry distribution chart, Procter & Gamble Health ranks #202 out of 351 companies in the Drug Manufacturers industry, placing it in the top 57.5%.
Is Procter & Gamble Health's PEG Ratio too high?
Procter & Gamble Health's current PEG Ratio of 2.14 is 17% below median its 10-year median of 2.59. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 8.11. The Drug Manufacturers industry median PEG Ratio is 1.72. Procter & Gamble Health's value of 2.14 is 24.4% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #202 out of 351 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #202 out of 351 companies for PEG Ratio. This places Procter & Gamble Health in the lower half of its industry. The industry median PEG Ratio is 1.72. Procter & Gamble Health's value of 2.14 is 24.4% above this benchmark. Historically, Procter & Gamble Health's own PEG Ratio has ranged from 1.19 to 8.11 over the past decade. While the company's 10-year median is 2.59 vs. the industry median of 1.72, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 351 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current PEG Ratio of 2.14 is 24.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current PEG Ratio is 2.14, which is 17% below median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,112.54, compared to a current price of ₹6,490.60 — trading 6.2% above its estimated fair value. The current PEG Ratio is 2.14, which is 17% below median its 10-year median of 2.59 and 24.4% above the Drug Manufacturers industry median of 1.72. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current PEG Ratio is 2.14 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued.
The current stock price of ₹6,490.60 is trading 6.2% above its estimated GF Value™ of ₹6,112.54.
GuruFocus considers Procter & Gamble Health to be Fairly Valued.
Key valuation signals for BOM:500126:
PEG Ratio: 2.14 (17% below median its 10-year median of 2.59)
GF Value™: ₹6,112.54 vs. price of ₹6,490.60 (6.2% above fair value)
Industry Position: 24.4% above the Drug Manufacturers median (#202 of 351)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score
Get the complete analysis for BOM:500126
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
